Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography.
D000328:Adult; D000368:Aged; D001549:Benzamides; D002851:Chromatography, High Pressure Liquid / Q000379:methods* / Q000592:standards; D004252:DNA Mutational Analysis / Q000379:methods* / Q000592:standards; D004273:DNA, Neoplasm / Q000235:genetics; D004351:Drug Resistance / Q000235:genetics; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics; D008297:Male; D008875:Middle Aged; D016374:Oncogene Proteins v-abl / Q000737:chemistry / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use; D017434:Protein Structure, Tertiary; D011743:Pyrimidines / Q000627:therapeutic use; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity
D001549:Benzamides; D004273:DNA, Neoplasm; D016374:Oncogene Proteins v-abl; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate